VivoSim Labs (VIVS) Share-based Compensation (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Share-based Compensation of $86000.0 for Q1 2026, down 5.49% year-over-year from $91000.0 in Q1 2025, and up 28.36% quarter-over-quarter from $67000.0 in Q4 2025.
VivoSim Labs (VIVS) Share-based Compensation (2011 - 2026) Analysis & Trends
VivoSim Labs' Share-based Compensation history runs 16 years deep, the most recent figure standing at $86000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation fell 5.49% year-over-year to $86000.0; the TTM figure through Mar 2026 stood at $303000.0 (down 43.05% YoY), while the FY2026 annual figure was $303000.0, down 43.05% from the prior year.
- Share-based Compensation for Q1 2026 stood at $86000.0, up from $67000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $675000.0 in Q3 2023, with the low at $67000.0 in Q4 2025.
- The 5-year median for Share-based Compensation is $156500.0 (2023), against an average of $295000.0.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation soared 59.04% in 2022, then plunged 77.04% in 2024.
- VivoSim Labs' Share-based Compensation stood at $544000.0 in 2022, then plunged by 71.14% to $157000.0 in 2023, then slipped by 17.2% to $130000.0 in 2024, then tumbled by 48.46% to $67000.0 in 2025, then advanced by 28.36% to $86000.0 in 2026.
- Business Quant data shows VIVS's Share-based Compensation at $86000.0 in Q1 2026, $67000.0 in Q4 2025, and $72000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | VivoSim Labs | 1.51 Mn | 1.51 Mn | - | 91,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91,000.00 |
| Jun 30, 2026 | 91,000.00 |
| Mar 31, 2026 | 86,000.00 |
| Mar 31, 2026 | 86,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Dec 31, 2025 | 67,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Dec 31, 2024 | 130,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 201,000.00 |
| Mar 31, 2024 | 201,000.00 |